1. Home
  2. XBIT vs XLO Comparison

XBIT vs XLO Comparison

Compare XBIT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.15

Market Cap

69.8M

Sector

Health Care

ML Signal

SELL

XLO

Xilio Therapeutics Inc.

SELL

Current Price

$9.02

Market Cap

56.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
XBIT
XLO
Founded
2005
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.8M
56.9M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
XBIT
XLO
Price
$2.15
$9.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 37.4K
8.7K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$30.47
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$2.09
$0.46
52 Week High
$3.44
$25.17

Technical Indicators

Market Signals
Indicator
XBIT
XLO
Relative Strength Index (RSI) 39.61 47.47
Support Level N/A $8.52
Resistance Level $2.46 $9.46
Average True Range (ATR) 0.07 0.35
MACD -0.00 -0.00
Stochastic Oscillator 0.00 26.17

Price Performance

Historical Comparison
XBIT
XLO

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: